NCT04502030已完成3 期
Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Octapharma
- 入组人数
- 247
- 试验地点
- 85
- 主要终点
- Occurrence of major infections
研究概览
简要总结
Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Treatment-naïve or relapsed/refractory CLL patients undergoing CLL antineoplastic treatment. Diagnosis of B-cell CLL established according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria and documented within medical records.
- •Hypogammaglobulinemia (IgG levels <5 g/L) as confirmed by the Central Laboratory.
- •≥18 years of age.
- •Voluntarily given, fully informed written and signed consent obtained before any study-related procedures are conducted.
排除标准
- •IgG treatment within 3 months prior to Screening.
- •Antibiotic prophylaxis and/or treatment within 7 days prior to Baseline (with the exception of trimethoprim-sulfamethoxazole [TMP/SMX], diaminodiphenyl sulfone [dapsone] and pentamidine inhalation).
- •Current major infection or >1 major infection in the previous 6 months before Baseline.
- •History of anaphylaxis or severe systemic response to immunoglobulin, blood or plasma-derived products or any Panzyga component.
- •History of a non-CLL malignancy or other medical condition with life-expectancy of less than two years.
- •Severe liver disease, with signs of ascites and/or hepatic encephalopathy.
- •Severe kidney disease (as defined by estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2).
- •Body weight >140 kg.
- •Eastern Cooperative Oncology Group (ECOG) performance score of >2 (Appendix 1).
- •Female patients of childbearing potential unwilling to use a protocol-required method of contraception (as per protocol section 7.3.9 b) from the Screening Visit throughout the study treatment period and for 30 days following the last dose of study drug.
- •Human immunodeficiency virus (HIV) infection at Screening (defined for the study as positive HIV antibody test).
- •Patients found to be chronic carriers of hepatitis B virus (HBV), defined by positive surface antigen (HBsAg), positive Hepatitis B core antibodies (HBcAb) and/or low HBV titers, who will not receive targeted antiviral therapy while undergoing CLL therapy, and patients with active HBV, defined as high HBV titers.
- •Uncontrolled hepatitis C infection at Screening (defined for the study as positive hepatitis virus C [HCV] polymerase chain reaction [PCR]).
- •Pregnant and lactating women.
- •Subjects with a history of thromboembolic events (TEE) such as deep vein thrombosis, pulmonary embolism, myocardial infarction, ischemic stroke, transient ischemic attack, peripheral artery disease (Fontaine IV) within 6 months before Baseline.
- •Planned or ongoing immunosuppressive treatment (other than for CLL or corticosteroids) or other forbidden medication during the entire study duration after study enrollment.
- •Participation in another interventional clinical trial that is either blinded or involves an investigational (not approved) product within 3 months before Baseline or during the course of the clinical study. Participation in observational clinical trials or open-label trials involving an approved product may be permitted after consultation with the medical monitor.
- •Known IgA deficiency with antibodies to IgA.
- •Known blood hyperviscosity, or other hypercoagulable states.
- •Patients unable or unwilling to understand or comply with the study protocol.
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo (Other)
Panzyga
Experimental
干预措施: Panzyga (Biological)
结局指标
主要结局
Occurrence of major infections
时间窗: 52 weeks
Major infection for this trial is defined as: * Bacterial and/or viral infections resulting in death * Bacterial and/or viral infections, which are microbiologically documented (MDI) or clinically documented (CDI) requiring treatment with anti-infectives; upper respiratory tract infections, bronchitis, lower urinary tract infections, localized skin infections and stomatitis (MDI or CDI) are considered major only if they require treatment with antiinfectives AND hospitalization or hospitalization prolongation. * Fever of unknown origin (FUO) requiring hospitalization or hospitalization prolongation
次要结局
- Overall infection rate(52 weeks)
- Duration of prophylaxis with anti-infectives(52 weeks)
- Frequency of prophylaxis with anti-infectives(52 weeks)
研究者
研究点 (85)
Loading locations...
相似试验
已完成
3 期
Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral InfectionsInfluenza, HumanAcute Respiratory InfectionFluViral InfectionCommon ColdNCT03189537Valenta Pharm JSC400
已完成
1 期
Phase 1 Norwalk Vaccine StudyNorovirusNCT00806962LigoCyte Pharmaceuticals, Inc.61
已完成
3 期
Safety and Immunological Efficacy of the Pentavalent Rotavirus Vaccine - Rota-V-Aid™ (Live Attenuated Oral, Freeze-dried) at Healthy Adults Aged 18 to 45 Years.Rotavirus InfectionsRotavirus VaccinesNCT05037435Limited Liability Company Pharm Aid40
尚未招募
不适用
Efficacy and Safety of Chiglitazar Added to Glargine in Patients With Type 2 DiabetesEfficacy and Safety of Chiglitazar Sodium in the Treatment of T2DM PatientsMetformin Combined With Insulin Glargine in the Treatment of Type 2 Diabetes Patients Who Still Have Poor Hypoglycemic Effect128 Patients Were Randomly Assigned 1:1Metformin and Insulin Glargine Combined With Chiglitazar Sodium Tablets 48mg/ Day GroupMetformin and Insulin Glargine Combined With Placebo GroupInvestigatorInitiate TrialChanges in HbA1C From Baseline at 18 Weeks of TreatmentNCT06007014Yanbing Li128
招募中
2 期
Clinical Trial to Study the Efficacy and Safety of Fluorothiazinone (N.F. Gamaleya NRCEM) in Prophylaxis of Nosocomial Bacterial Infections With Participation of Patients on MVGram Negative PneumoniaGram-Negative Bacterial InfectionsBacteremia Caused by Gram-Negative BacteriaNCT06135350Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation234